Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders? - PubMed (original) (raw)
Review
Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?
Manfred Windisch et al. Curr Alzheimer Res. 2007 Dec.
Abstract
Since the discovery that mutations of alpha-synuclein (AS) gene are responsible for rare forms of familiar Parkinson's disease this synaptic protein attracted increased interest. AS is the main constituent of Lewy bodies. In spite the physiological function is still unclear there is an ongoing discussion if over-expression is already dangerous, or if toxicity is subjected to oligomers, protofibrilles or mature aggregates. The fact that the central hydrophobic part of AS is a constituent of amyloid plaques in Alzheimer patients and the finding that a majority of AD patients have Lewy bodies and Lewy neurites in specific brain areas, raised our interest in the possible contribution of AS to pathogenesis of AD. Beta-synuclein (betaS) a protein of the same gene family seems to be a naturally occurring anti aggregatory factor preventing AS aggregation in vitro and in vivo. The N-terminal amino acid sequence 1 to 15 is responsible for this effect. Based on this finding we synthesized a peptide library with different sequence variations. Several of these peptides displayed distinct neuroprotective activity in tissue culture models of neurodegeneration induced by oxidative stress or Abeta1-42. In spite these peptides have a short half-life, in vivo significant reduction in brain plaque load and improvement of behavioral deficits was demonstrated in an APP-tg mouse model after intranasal treatment for 2 months. KEGV, the shortest sequence was also active after intraperitoneal application. Neuroprotective data in tissue cultures and results from transgenic mice are some how in conflict because in vitro effects can not be explained by the antiaggregatory potential, but most likely by interaction of betaS derivates with anti-apoptotic PI3/Akt cell signaling or interference with anti-oxidative pathways (JNK/JIB). The possibility that such betaS derived peptidomimetics might act as neuroprotectants and at the same time prevent protein missfolding suggests possible therapeutic usefulness in different neurodegenerative disorders.
Similar articles
- The role of alpha-synuclein in neurodegenerative diseases: a potential target for new treatment strategies?
Windisch M, Wolf H, Hutter-Paier B, Wronski R. Windisch M, et al. Neurodegener Dis. 2008;5(3-4):218-21. doi: 10.1159/000113707. Epub 2008 Mar 6. Neurodegener Dis. 2008. PMID: 18322395 Review. - Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders?
Windisch M, Wolf HJ, Hutter-Paier B, Hofmeister A, Wronski R. Windisch M, et al. Curr Alzheimer Res. 2007 Sep;4(4):446-57. doi: 10.2174/156720507781788783. Curr Alzheimer Res. 2007. PMID: 17908049 Review. - Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?
Windisch M, Hutter-Paier B, Schreiner E, Wronski R. Windisch M, et al. J Mol Neurosci. 2004;24(1):155-65. doi: 10.1385/JMN:24:1:155. J Mol Neurosci. 2004. PMID: 15314265 - Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
Olanow CW, Brundin P. Olanow CW, et al. Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Mov Disord. 2013. PMID: 23390095 Review. - Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides.
Windisch M, Hutter-Paier B, Rockenstein E, Hashimoto M, Mallory M, Masliah E. Windisch M, et al. J Mol Neurosci. 2002 Aug-Oct;19(1-2):63-9. doi: 10.1007/s12031-002-0012-8. J Mol Neurosci. 2002. PMID: 12212795
Cited by
- Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases.
Staff NP, Jones DT, Singer W. Staff NP, et al. Mayo Clin Proc. 2019 May;94(5):892-905. doi: 10.1016/j.mayocp.2019.01.001. Mayo Clin Proc. 2019. PMID: 31054608 Free PMC article. Review. - Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial.
Low PA, Robertson D, Gilman S, Kaufmann H, Singer W, Biaggioni I, Freeman R, Perlman S, Hauser RA, Cheshire W, Lessig S, Vernino S, Mandrekar J, Dupont WD, Chelimsky T, Galpern WR. Low PA, et al. Lancet Neurol. 2014 Mar;13(3):268-75. doi: 10.1016/S1474-4422(13)70301-6. Epub 2014 Feb 5. Lancet Neurol. 2014. PMID: 24507091 Free PMC article. Clinical Trial. - Stability of clinical etiologic diagnosis in dementia and mild cognitive impairment: results from a multicenter longitudinal database.
Koepsell TD, Gill DP, Chen B. Koepsell TD, et al. Am J Alzheimers Dis Other Demen. 2013 Dec;28(8):750-8. doi: 10.1177/1533317513504611. Am J Alzheimers Dis Other Demen. 2013. PMID: 24363072 Free PMC article. - Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy.
Ubhi K, Rockenstein E, Mante M, Patrick C, Adame A, Thukral M, Shults C, Masliah E. Ubhi K, et al. Neuroreport. 2008 Aug 27;19(13):1271-6. doi: 10.1097/WNR.0b013e32830b3661. Neuroreport. 2008. PMID: 18695506 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous